AIRLINK 62.48 Increased By ▲ 2.05 (3.39%)
BOP 5.36 Increased By ▲ 0.01 (0.19%)
CNERGY 4.58 Decreased By ▼ -0.02 (-0.43%)
DFML 15.50 Increased By ▲ 0.66 (4.45%)
DGKC 66.40 Increased By ▲ 1.60 (2.47%)
FCCL 17.59 Increased By ▲ 0.73 (4.33%)
FFBL 27.70 Increased By ▲ 2.95 (11.92%)
FFL 9.27 Increased By ▲ 0.21 (2.32%)
GGL 10.06 Increased By ▲ 0.10 (1%)
HBL 105.70 Increased By ▲ 1.49 (1.43%)
HUBC 122.30 Increased By ▲ 4.78 (4.07%)
HUMNL 6.60 Increased By ▲ 0.06 (0.92%)
KEL 4.50 Decreased By ▼ -0.05 (-1.1%)
KOSM 4.48 Decreased By ▼ -0.09 (-1.97%)
MLCF 36.20 Increased By ▲ 0.79 (2.23%)
OGDC 122.92 Increased By ▲ 0.53 (0.43%)
PAEL 23.00 Increased By ▲ 1.09 (4.97%)
PIAA 29.34 Increased By ▲ 2.05 (7.51%)
PIBTL 5.80 Decreased By ▼ -0.14 (-2.36%)
PPL 107.50 Increased By ▲ 0.13 (0.12%)
PRL 27.25 Increased By ▲ 0.74 (2.79%)
PTC 18.07 Increased By ▲ 1.97 (12.24%)
SEARL 53.00 Decreased By ▼ -0.63 (-1.17%)
SNGP 63.21 Increased By ▲ 2.01 (3.28%)
SSGC 10.80 Increased By ▲ 0.05 (0.47%)
TELE 9.20 Increased By ▲ 0.71 (8.36%)
TPLP 11.44 Increased By ▲ 0.86 (8.13%)
TRG 70.86 Increased By ▲ 0.95 (1.36%)
UNITY 23.62 Increased By ▲ 0.11 (0.47%)
WTL 1.28 No Change ▼ 0.00 (0%)
BR100 6,944 Increased By 65.8 (0.96%)
BR30 22,827 Increased By 258.6 (1.15%)
KSE100 67,142 Increased By 594.3 (0.89%)
KSE30 22,090 Increased By 175.1 (0.8%)
World

Roche joins Moderna to include antibody test in COVID-19 vaccine trial

  • "This could play a role in assessing if, or when, an individual needs revaccination, or in helping to answer other clinically relevant questions," Roche said in a statement.
Published December 9, 2020

ZURICH: Roche is partnering with Moderna to include a COVID-19 antibody test in the mRNA specialist's ongoing vaccine trials, the Swiss drugmaker said on Wednesday, potentially demonstrating if the vaccine is working.

Roche said the test, which received US Food and Drug Administration emergency use approval in November, can provide quantitative evidence of the presence and levels of antibodies that develop in response to Moderna's vaccine candidate.

Moderna's vaccine, which in late-stage trials with more than 30,000 participants showed efficacy of 94% in preventing COVID-19, is designed to trigger an antibody response to proteins found on the coronavirus spike's receptor binding domain, the part of the virus that gains entry to human cells.

Roche said its test, conducted in a laboratory setting and requiring a blood draw, can establish a correlation between vaccine-induced protection and levels of receptor-binding domain antibodies.

"This could play a role in assessing if, or when, an individual needs revaccination, or in helping to answer other clinically relevant questions," Roche said in a statement.

Until now, demand for so-called molecular tests to detect active COVID-19 disease from Roche and other manufacturers has far exceeded supply, though there has been less demand for so-called antibody tests that help determine if a person has been exposed to the new coronavirus and has recovered.

Roche hopes with new tests like the one it is pairing with Moderna's trial will help boost demand for antibody tests, too.

Comments

Comments are closed.